Novo Nordisk’s type two diabetes treatment for adults approved in japan
The Japanese Ministry of Health, Labour and Welfare has approved Novo Nordisk’s treatment for type 2 diabetes adult patients, new…
Pharmaceuticals, Biotechnology and Life Sciences
The Japanese Ministry of Health, Labour and Welfare has approved Novo Nordisk’s treatment for type 2 diabetes adult patients, new…
Novo Nordisk has submitted a Biologics License Applications (BLA) to the US Food and Drug Administration (FDA) and a Marketing…
Novo Nordisk has completed the first phase 3a trial, PIONEER 1, with oral semaglutide, for treating type 2 diabetes in…
Novo Nordisk has published the results for semaglutide from a study aiming to test the treatment for type 2 diabetes.
Novo Nordisk on Monday confirmed proposing on December 22, 2017 to acquire Ablynx for €28.00 per share in cash and…
People with either type 1 or type 2 diabetes treated with Tresiba had fewer episodes of low blood sugar (hypoglycaemia) compared…
Switching to Tresiba from another basal insulin benefits people with diabetes regardless of whether or not their blood sugar levels…
To mark World Heart Day, the International Diabetes Federation (IDF) has partnered with Novo Nordisk to launch the first-ever multi-country online survey investigating the level of CVD awareness and knowledge among people living with type 2 diabetes.
China Food and Drug Administration (CFDA) has approved Novo Nordisk’s Tresiba (insulin degludec) for the treatment of diabetes in China.